Key result
The age-standardized prevalence of diabetes in China increased from 7.53% in 2005 to 13.67% in 2023, representing an estimated 233 million individuals living with the condition.
Why the study?
Comprehensive estimates and projections of diabetes prevalence and non-fatal burden at both regional and national levels were lacking in China despite substantial subnational disparities.
Observational
Effect estimate: nearly 50% increase
Absolute Event Rate: 13.67% vs 7.53%
The prevalence and disease burden of diabetes in China have increased significantly from 2005 to 2023, highlighting an urgent need for effective obesity interventions to curb future growth.
No takes yet. Share an insight, caveat, or question.
China's rising diabetes burden may require heightened clinical vigilance; leaves open optimal interventions for prospective trials.
Liu et al. (2025) conducted an observational in Diabetes. Year 2023 vs. Year 2005 was evaluated on Age-standardized rate (ASR) of diabetes prevalence (nearly 50% increase). The age-standardized prevalence of diabetes in China increased from 7.53% in 2005 to 13.67% in 2023, representing an estimated 233 million individuals living with the condition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: